ReviewCancer metastasis reviews2020
The role of fibroblast activation protein in health and malignancy.
Review in Cancer metastasis reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05030597 (Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma), which is not on this map. Cited by 345 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
Who cites it
345 citing papers in PubMed, 3 syntheses or guidelines pooled it, 543 citations in OpenAlex.
- Predicting fibroblast activation protein overexpression in the overall survival rate of cancer patients: a systematic review and meta-analysis.Systematic reviews · 2025Pooled it
- Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Therapeutic potential of FAPI RLT in oncology: A systematic review.Theranostics · 2025Pooled it
- 177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Feasibility and therapeutic potential of [European journal of nuclear medicine and molecular imaging · 2024Trial
- Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Trial
- Preclinical evaluation of homodimeric FAPI target modules for UniCAR-mediated targeting of FAP-expressing tumor and stromal cells.Oncoimmunology · 2026Article
- Integrated Multi-Time-PointMedComm · 2026Article
- Context-dependent efficacy of fibroblast activation protein-targeted radionuclide therapy (FAP-TRT): the dual role of CAFs.European journal of nuclear medicine and molecular imaging · 2026Article
- Reproductive factors and the expression of stromal markers in benign breast biopsy samples.British journal of cancer · 2026Article
- Article
- The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors.Science advances · 2026Article
- [Research square · 2026Article
- The value of fibroblast activation protein inhibitor-based radionuclide theranostics in sarcoma: a systematic review.Annals of nuclear medicine · 2026Review
- Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Clinical Evaluation of [European journal of nuclear medicine and molecular imaging · 2026Article
- Intra-patient comparison of tracer uptake and biodistribution of [Annals of nuclear medicine · 2026Article
- The Evolution of FAP-Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications.International journal of molecular sciences · 2026Review
- A shark variable new antigen receptor recognizes an occluded epitope of fibroblast activation protein.bioRxiv : the preprint server for biology · 2026Article
- Tuning the Structural Properties of a Single-Domain Antibody Scaffold for Improved Fibroblast Activation Protein Targeting.Molecular pharmaceutics · 2026Article
285 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Fibroblast activation protein-α (FAP) is a type-II transmembrane serine protease expressed almost exclusively to pathological conditions including fibrosis, arthritis, and cancer. Across most cancer types, elevated FAP is associated with worse clinical outcomes. Despite the clear association between FAP and disease severity, the biological reasons underlying these clinical observations remain unclear. Here we review basic FAP biology and FAP's role in non-oncologic and oncologic disease. We further explore how FAP may worsen clinical outcomes via its effects on extracellular matrix remodeling, intracellular signaling regulation, angiogenesis, epithelial-to-mesenchymal transition, and immunosuppression. Lastly, we discuss the potential to exploit FAP biology to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.